Prothena Corporation plc ( PRTA ) NASDAQ Global Select

Cena: 8.78 ( 2.63% )

Aktualizacja 08-22 21:58
NASDAQ Global Select
Branża: Biotechnology
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Prothena Corporation Plc, późna firma kliniczna, koncentruje się na odkrywaniu i rozwoju nowych terapii zagrażających życiu chorób w Stanach Zjednoczonych. Firma bierze udział w rozwoju Birtamimab, badanego humanizowanego przeciwciała, które jest w badaniu klinicznym fazy III w leczeniu amyloidozy Al; Prasinezumab, humanizowane przeciwciało monoklonalne, które jest w fazie badań klinicznych IIB w leczeniu choroby Parkinsona; PRX004, które zakończyło badanie kliniczne fazy I do leczenia amyloidozy przeztrentyny; i PRX005, który jest w badaniu klinicznym fazy I w leczeniu choroby Alzheimera. Jego programy odkrywania i przedkliniczne obejmują PRX012 do leczenia choroby Alzheimera; oraz podwójna szczepionka szczepionki Aß-tau do leczenia i zapobiegania chorobie Alzheimera. Prothena Corporation Plc ma umowę o licencji, rozwoju i komercjalizacji z F. Hoffmann-La Roche Ltd. i Hoffmann-La Roche Inc. w celu opracowania i komercjalizacji przeciwciał skierowanych do alfa-synukleiny; oraz umowa o współpracy z Bristol-Myers Squibb w celu opracowania przeciwciał. Firma została założona w 2012 roku i ma siedzibę w Dublinie w Irlandii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 173
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 71.19003
Ilość akcji: Brak danych
Debiut giełdowy: 2012-12-18
WWW: https://www.prothena.com
CEO: Dr. Gene G. Kinney Ph.D.
Adres: 77 Sir John Rogerson’s Quay
Siedziba: 2 Dublin
ISIN: IE00B91XRN20
Wskaźniki finansowe
Kapitalizacja (USD) 472 896 550
Aktywa: 595 254 000
Cena: 8.78
Wskaźnik Altman Z-Score: 5.1
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -1.6
Ilość akcji w obrocie: 71%
Średni wolumen: 1 586 948
Ilość akcji 53 830 000
Wskaźniki finansowe
Przychody TTM 133 350 000
Zobowiązania: 60 892 000
Przedział 52 tyg.: 4.32 - 22.83
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -5.6
P/E branży: 28.3
Beta: 0.158
Raport okresowy: 2025-10-30
WWW: https://www.prothena.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Tran B. Nguyen M.B.A. Chief Financial Officer & Chief Strategy Officer 830 145 1974
Dr. Hideki Garren M.D., Ph.D. Chief Medical Officer 808 708 1965
Mr. Brandon S. Smith Chief Operating Officer 757 790 1975
Ms. Carol D. Karp Chief Regulatory Officer 701 480 1953
Mr. Michael J. Malecek Chief Legal Officer 588 250 1966
Dr. Wagner M. Zago Chief Scientific Officer 478 789 1973
Dr. Gene G. Kinney Ph.D. President, Chief Executive Officer & Director 1 004 809 1969
Mr. Mark C. Johnson C.F.A. Vice President of Investor Relations 0 0
Ms. Karin L. Walker CPA Chief Accounting Officer & Controller 0 1963
Mr. David A. Ford Chief People Officer 0 1970
Lista ETF z ekspozycją na akcje Prothena Corporation plc
Symbol ETF Ilość akcji Wartość
IWM 946 965 6 505 652
IWN 303 559 2 085 451
IBB 259 473 1 782 580
VTWO 197 361 1 197 981
SCHA 177 086 1 205 697
ESML 126 511 870 395
DFAS 97 748 671 528
VHT 92 487 561 396
DFAT 92 227 633 599
ZPRR.DE 68 372 411 928
R2SC.L 68 372 356 463
R2US.L 68 372 470 399
SXRG.DE 64 462 387 406
CUSS.L 64 462 442 851
CSUSS.MI 64 462 387 406
CUS1.L 64 462 335 185
AVSC 56 051 385 630
ITOT 48 760 334 980
NUSC 42 731 650 793
IWO 34 917 239 878
BTEE.L 31 091 213 596
2B70.DE 31 091 186 854
BTEC.L 31 091 213 596
BTEK.L 31 091 161 666
WLDS.L 29 945 155 704
WSML.L 29 945 205 718
IUSN.DE 29 945 179 962
XRS2.DE 27 325 164 387
XRSU.L 27 325 187 720
XRSG.L 27 325 14 225 294
SBIO 25 740 176 833
BBC 24 000 164 880
VTWV 23 233 141 024
DFAC 23 223 159 542
RSSL 19 580 134 514
EES 19 265 132 350
FHLC 14 317 98 357
IWV 10 684 73 395
PRFZ 9 852 67 781
WSCR.L 8 547 59 228
QQQS 8 272 56 911
XSU.TO 6 800 64 600
MNTL 6 351 43 694
ZPRS.DE 4 723 28 455
WOSC.L 4 723 24 623
WDSC.L 4 723 32 494
UWM 3 924 26 957
SPGM 3 787 26 108
IBRN 3 418 23 481
DFAU 3 306 22 712
VTHR 3 260 19 788
URTY 3 248 22 313
VTWG 3 158 19 169
EWSA.AS 3 070 21 094
CBUG.DE 3 070 18 453
DFUS 2 713 18 638
USSC.L 2 462 14 754
ZPRV.DE 2 462 12 920
BIB 1 983 13 623
IBBQ 1 917 13 188
XUU.TO 888 8 435
XGRO.TO 614 5 836
XBAL.TO 283 2 686
XUH.TO 131 901
XAW.TO 111 1 052
HDG 47 322
XCNS.TO 22 210
XTR.TO 5 36
SBIO.MI 0 94 983
SC0K.DE 0 22 183
USUE.DE 0 0
USFM.L 0 0
RTYS.L 0 25 318
PZW.TO 0 314
SBIO.L 0 108 403
Wiadomości dla Prothena Corporation plc
Tytuł Treść Źródło Aktualizacja Link
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025 PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025. zacks.com 2025-05-09 18:30:22 Czytaj oryginał (ang.)
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. benzinga.com 2025-05-09 11:16:56 Czytaj oryginał (ang.)
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates Prothena (PRTA) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $1.34 per share a year ago. zacks.com 2025-05-08 22:50:36 Czytaj oryginał (ang.)
Prothena Reports First Quarter 2025 Financial Results and Business Highlights DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the first quarter of 2025 and provided business highlights. businesswire.com 2025-05-08 20:05:00 Czytaj oryginał (ang.)
Prothena to Report First Quarter 2025 Financial Results on May 8 DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. businesswire.com 2025-05-01 20:05:00 Czytaj oryginał (ang.)
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter. zacks.com 2025-02-21 16:50:26 Czytaj oryginał (ang.)
Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript Prothena Corporation plc (NASDAQ:PRTA ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President and Chief Executive Officer Chad Swanson - Chief Development Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Brandon Smith - Chief Operating Officer Conference Call Participants Emma Seymour - Piper Sandler Jay Olson - Oppenheimer Umer Raffat - Evercore Charles Duncan - Cantor Fitzgerald Jason Butler - Citizens JMP Michael Yee - Jefferies Rudy Li - Chardan Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Operator Good day, ladies and gentlemen, and welcome to the Prothena Biosciences Fourth Quarter and Full Year 2024 Financial Results Conference Call. My name is Pam, and I will be your coordinator for today. seekingalpha.com 2025-02-20 22:45:53 Czytaj oryginał (ang.)
Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates Prothena (PRTA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1.26 per share a year ago. zacks.com 2025-02-20 20:25:26 Czytaj oryginał (ang.)
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena reported financial results for the 4th quarter and full year 2024. The Company also provided business highlights and 2025 financial guidance. businesswire.com 2025-02-20 18:05:00 Czytaj oryginał (ang.)
Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prothena Corporation PLC (NASDAQ: PRTA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. globenewswire.com 2025-02-17 20:10:00 Czytaj oryginał (ang.)
Prothena Announces Board of Directors Update DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced that Oleg Nodelman will step down from Prothena's Board of Directors to create time to focus on existing and new endeavors. businesswire.com 2024-12-30 18:05:00 Czytaj oryginał (ang.)
Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced results from PADOVA study conducted by partner Roche investigating prasinezumab in early-stage Parkinson's disease. businesswire.com 2024-12-19 03:05:00 Czytaj oryginał (ang.)
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report? Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-12-12 14:36:18 Czytaj oryginał (ang.)
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter. zacks.com 2024-11-13 10:51:11 Czytaj oryginał (ang.)
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates Prothena (PRTA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to earnings of $0.38 per share a year ago. zacks.com 2024-11-12 21:00:42 Czytaj oryginał (ang.)
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts? Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week. zacks.com 2024-11-11 13:50:15 Czytaj oryginał (ang.)
Prothena to Report Third Quarter 2024 Financial Results on November 12 DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its third quarter and first nine months of 2024 financial results on Tuesday, November 12, 2024. businesswire.com 2024-11-05 18:05:00 Czytaj oryginał (ang.)
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock? Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2024-10-29 15:01:18 Czytaj oryginał (ang.)
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength? Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com 2024-10-29 07:50:29 Czytaj oryginał (ang.)
Prothena Announces Leadership Team Updates DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer. businesswire.com 2024-09-27 20:05:00 Czytaj oryginał (ang.)
What Makes Prothena (PRTA) a New Buy Stock Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2024-08-19 17:01:05 Czytaj oryginał (ang.)
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY. zacks.com 2024-08-09 14:21:08 Czytaj oryginał (ang.)
Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates Prothena (PRTA) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of a loss of $1.01 per share. This compares to loss of $1.03 per share a year ago. zacks.com 2024-08-08 23:41:15 Czytaj oryginał (ang.)
Prothena to Report Second Quarter 2024 Financial Results on August 8 DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its second quarter and first six months of 2024 financial results on Thursday, August 8, 2024. businesswire.com 2024-08-01 20:05:00 Czytaj oryginał (ang.)
Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-07-25 15:07:28 Czytaj oryginał (ang.)
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last? Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. zacks.com 2024-06-24 13:50:36 Czytaj oryginał (ang.)
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win Eli Lilly stock reversed premarket gains at the open Tuesday after an FDA panel endorsed its Alzheimer's treatment, donanemab. investors.com 2024-06-11 16:20:35 Czytaj oryginał (ang.)
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report? Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-06-07 16:36:18 Czytaj oryginał (ang.)
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases. zacks.com 2024-05-29 15:31:07 Czytaj oryginał (ang.)
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million. businesswire.com 2024-05-28 20:05:00 Czytaj oryginał (ang.)